Literature DB >> 24900335

Ranking high affinity ligands of low solubility by NMR spectroscopy.

Isabelle Landrieu1, Xavier Hanoulle1, Bernd Fritzinger1, Dragos Horvath2, Jean-Michel Wieruszeski1, Guy Lippens1.   

Abstract

Cyclosporine A (CsA) and its chemical analogues EthVal4Cs, MeVal4Cs, and Me(d-Ala)3EthVal4Cs (Alisporivir) all interact with cyclophilin A (CypA). The latter Alisporivir is a nonimmunosuppressive CsA derivative that has potent anti-HCV properties in clinical trials. We show here that NMR spectroscopy can be used to rank this series of related pharmacological molecules despite their high affinity for the target protein and low solubility in water. The novel method is based on the possibility to detect distinct NMR signals from the different protein complexes in a mixture. The method has enabled us to distinguish subtle effects of discrete chemical modifications of the parent molecule on the affinity of the ligands for the target protein.

Entities:  

Keywords:  Alisporivir; Nuclear magnetic resonance; cyclophilin A; ligands; proteins

Year:  2011        PMID: 24900335      PMCID: PMC4018068          DOI: 10.1021/ml200039u

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  8 in total

1.  Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis.

Authors:  Bas J H Kuipers; Harry Gruppen
Journal:  J Agric Food Chem       Date:  2007-06-01       Impact factor: 5.279

2.  A fluorescence polarization-based assay for peptidyl prolyl cis/trans isomerase cyclophilin A.

Authors:  Yaya Liu; Jianjun Jiang; Paul L Richardson; Rajarathnam D Reddy; Donald D Johnson; Warren M Kati
Journal:  Anal Biochem       Date:  2006-05-12       Impact factor: 3.365

3.  Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025.

Authors:  Isabelle Landrieu; Xavier Hanoulle; Fanny Bonachera; Arnaud Hamel; Nathalie Sibille; Yanxia Yin; Jean-Michel Wieruszeski; Dragos Horvath; Qun Wei; Grégoire Vuagniaux; Guy Lippens
Journal:  Biochemistry       Date:  2010-06-08       Impact factor: 3.162

4.  Interaction of cyclosporin A with an Fab fragment or cyclophilin. Affinity measurements and time-dependent changes in binding.

Authors:  G Zeder-Lutz; R Wenger; M H Van Regenmortel; D Altschuh
Journal:  FEBS Lett       Date:  1993-07-12       Impact factor: 4.124

5.  The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.

Authors:  Jan Paeshuyse; Artur Kaul; Erik De Clercq; Brigitte Rosenwirth; Jean-Maurice Dumont; Pietro Scalfaro; Ralf Bartenschlager; Johan Neyts
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

6.  Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions.

Authors:  A Billich; F Hammerschmid; P Peichl; R Wenger; G Zenke; V Quesniaux; B Rosenwirth
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

7.  Conformational polymorphism of cyclosporin A.

Authors:  D Altschuh; W Braun; J Kallen; V Mikol; C Spitzfaden; J C Thierry; O Vix; M D Walkinshaw; K Wüthrich
Journal:  Structure       Date:  1994-10-15       Impact factor: 5.006

8.  Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Authors:  Lotte Coelmont; Suzanne Kaptein; Jan Paeshuyse; Inge Vliegen; Jean-Maurice Dumont; Grégoire Vuagniaux; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

  8 in total
  1 in total

1.  Thermo-kinetic analysis space expansion for cyclophilin-ligand interactions - identification of a new nonpeptide inhibitor using Biacore™ T200.

Authors:  Martin A Wear; Matthew W Nowicki; Elizabeth A Blackburn; Iain W McNae; Malcolm D Walkinshaw
Journal:  FEBS Open Bio       Date:  2017-02-23       Impact factor: 2.693

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.